Gamida Cell and Amgen sign licensing agreement

Under the terms of the agreement, Amgen will receive a minority equity interest in Gamida Cell in addition to royalty payments from future sales of StemEx for hematological diseases. Gamida Cell will receive a non-exclusive license to manufacture and utilize a number of cytokines for StemEx manufacturing.

StemEx is being developed for treatment of hematological malignancies by Gamida Cell in a joint venture with Teva Pharmaceutical Industries.

Naftali Brikashvili, Gamida Cell CFO, said: “This agreement is of significant value to Gamida Cell both operationally and strategically.”